title: RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection.
abstract: OBJECTIVE
  To establish a method for morphometric analysis of retrogradely labeled retinal ganglion cells (RGCs) of the mouse retina, to be used for the study of molecular aspects of RGC survival and neuroprotection in this model; to evaluate the effect of overexpression of Cu-Zn-superoxide dismutase (CuZnSOD) on RGC survival after severe crush injury to the optic nerve, and to assess the effect of the alpha2-adrenoreceptor agonist brimonidine, recently shown to be neuroprotective, on RGC survival.
  
  
  METHODS
  A severe crush injury was inflicted unilaterally in the orbital portion of the optic nerves of wild-type and transgenic (Tg-SOD) mice expressing three to four times more human CuZnSOD than the wild type. In each mouse all RGCs were labeled 72 hours before crush injury by stereotactic injection of the neurotracer dye FluoroGold (Fluorochrome, Denver, CO) into the superior colliculus. Survival of RGCs was then assessed morphometrically, with and without systemic injection of brimonidine.
  
  
  RESULTS
  Two weeks after crush injury, the number of surviving RGCs was significantly lower in the Tg-SOD mice (596.6 +/- 71.9 cells/mm(2)) than in the wild-type control mice (863. 5 +/- 68 cells/mm(2)). There was no difference between the numbers of surviving RGCs in the uninjured retinas of the two strains (3708 +/- 231.3 cells/mm(2) and 3904 +/- 120 cells/mm(2), respectively). Systemic injections of brimonidine significantly reduced cell death in the Tg-SOD mice, but not in the wild type.
  
  
  CONCLUSIONS
  Overexpression of CuZnSOD accelerates RGC death after optic nerve injury in mice. Activation of the alpha2-adrenoreceptor pathway by brimonidine enhances survival of RGCs in an in vivo transgenic model of excessive oxidative stress.
authors.affiliation: Goldschleger Eye Institute, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel.
authors.forename: H
authors.initials: H
authors.lastname: Levkovitch-Verbin
authors.forename: C
authors.initials: C
authors.lastname: Harris-Cerruti
authors.forename: Y
authors.initials: Y
authors.lastname: Groner
authors.forename: L A
authors.initials: LA
authors.lastname: Wheeler
authors.forename: M
authors.initials: M
authors.lastname: Schwartz
authors.forename: E
authors.initials: E
authors.lastname: Yoles
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D000068438:Brimonidine Tartrate; D016923:Cell Death; D002470:Cell Survival / Q000187:drug effects*; D051379:Mice; D008822:Mice, Transgenic; D009409:Nerve Crush; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009900:Optic Nerve / Q000187:drug effects*; D020221:Optic Nerve Injuries / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D018384:Oxidative Stress; D011810:Quinoxalines / Q000494:pharmacology; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism*; D012165:Retinal Ganglion Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D000316:Adrenergic alpha-Agonists; D018696:Neuroprotective Agents; D011810:Quinoxalines; D018341:Receptors, Adrenergic, alpha-2; D000068438:Brimonidine Tartrate; D013482:Superoxide Dismutase